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Background: The PLATINUM randomized trial enrolled 1530 patients treated with either the platinum
chromium PROMUS Element everolimus-eluting stent (PtCr-EES; Boston Scientiﬁc, Natick, MA, USA) or
the predicate cobalt chromium PROMUS/XIENCE V EES (CoCr-EES; manufactured as XIENCE V by Abbott
Vascular, Santa Clara, CA, USA also distributed as PROMUS by Boston Scientiﬁc), including 124 patients
from Japanese sites. This substudy examines 2-year outcomes in the Japanese and non-Japanese cohorts.
Methods: Patients with 1 or 2 de novo native coronary artery lesions (baseline vessel diameter ≥2.50mm
to ≤4.25mm and length ≤24mm) were randomized 1:1 to PtCr-EES (N=63 patients in Japan) versus
CoCr-EES (N=61 patients in Japan).
Results: Several signiﬁcant differences were noted in baseline demographics, lesion characteristics, and
procedural technique between Japanese and non-Japanese patients, including longer ﬂuoroscopy time,
less use of contrast, and greater post-dilatation usage and maximum pressure in Japan. Dual antiplatelet
usage at 2 yearswas also higher in Japan. Despite these differences, the 2-year rates of target lesion failure
were comparable in patients treated with PtCr-EES and CoCr-EES both in Japan (3.2% vs 5.0% respectively,
p=0.68) and outside Japan (4.7% vs 5.9% respectively, p=0.33; p for interaction=0.82).
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Introduction
Although drug-eluting stents (DES) provide a clear reduction
in restenosis over bare metal stents (BMS), a risk of late adverse
clinical events remains with ﬁrst-generation stents [1,2]. Advances
in DES technology allow treatment of increasingly complex lesions
and patient conditions, potentially providing improved long-term
outcomes [3,4].
vier Ltd. All rights reserved.
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The contemporary PROMUS Element (Boston Scientiﬁc, Natick,
A, USA) and XIENCE V (PROMUS) (manufactured as XIENCE V
y Abbott Vascular, Santa Clara, CA, USA; also distributed as PRO-
USbyBoston Scientiﬁc) everolimus-eluting stents share the same
rug/polymer combination and have been shown in clinical tri-
ls to provide reduced revascularization, stent thrombosis, and
yocardial infarction rates compared toprior-generationDES [5,6].
he platinum chromium PROMUS Element stent is designed to be
oreﬂexible anddeliverable thanprior-generation stents [7]. One-
ear outcomes of the PLATINUM randomized controlled trial have
emonstrated that the PROMUS Element stent is non-inferior to
he XIENCE V (PROMUS) stent for target lesion failure (TLF) with no
igniﬁcant differences between stent types in safety measures [6].
omparable outcomes were maintained through 2 years, although
he PROMUS Element stent demonstrated lower revascularization
ates in the 1–2 year timeframe [8].
DES use in Japan has increased since the initial approval of
he ﬁrst-generation Cypher (Cordis, Bridgewater, NJ, USA) [9] and
AXUS Express (Boston Scientiﬁc) [10] stents in 2004 and 2007,
espectively. DES usage rates in 2007 were reported at 23% and
6% for angina pectoris and acute myocardial infarction patients,
espectively, among all treatment options available (including
edical therapy) [11]. The percentage of stent procedures using
ES in Japan increased from an estimated 66% in 2007 to 75% in
011 [6].
Past studies have suggested a more aggressive stent deploy-
ent strategy in Japan, including greater usage of post-dilatation,
igher implantation pressure, andmore frequent use of intravascu-
ar ultrasound guidance [9,12,13], possibly resulting in lower rates
f acute stent thrombosis [12]. Due to both the increased DES pen-
tration rate in Japan and the potential for geographical differences
n patient characteristics and practice patterns, it is important that
ovel stents be evaluated speciﬁcally in Japanese populations.
The current paper describes outcomes of the Japanese cohort of
he PLATINUM randomized controlled trial in order to (1) deter-
ine whether the observed similarity in outcomes between the
ROMUS Element and XIENCE V (PROMUS) stents is also seen in
apanese patients and (2) compare practice patterns and outcomes
n Japanese versus non-Japanese patients.
aterials and methods
evice description
The test device is the PROMUS Element everolimus-eluting
tent (PtCr-EES), which consists of a platinum chromium balloon-
xpandable stent with a dual-layer polymer coating containing
00g/cm2 of the immunosuppressive and antiproliferative agent
verolimus [14]. The drug and polymer coating of the PtCr-EES are
dentical to those used in the control device, a cobalt chromium
verolimus-eluting stent (CoCr-EES). The Element scaffold of the
tCr-EES was designed to provide improved deliverability, ves-
el conformability, side-branch access, radiopacity, radial strength,
nd fracture resistance [7,15].
ethods
The study protocols were approved by local ethics committees
nd/or Institutional Review Boards, and all patients provided writ-
en informed consent prior to enrollment. The PLATINUM study is
egistered on clinicaltrials.gov under NCT00823212.Detailed methods of the PLATINUM study have been previ-
usly described [6]. Brieﬂy, patients ≥18 years of age with stable
r unstable angina pectoris or documented silent ischemia were
onsidered for enrollment. Eligible patients with 1 or 2 de novology 64 (2014) 105–112
native coronary artery lesions (baseline vessel diameter ≥2.50mm
to ≤4.25mm, lesion length ≤24mm, and diameter stenosis ≥50%
to <100% with Thrombolysis In Myocardial Infarction ﬂow 2 or 3
by visual estimate) were randomized 1:1 to PtCr-EES versus CoCr-
EES. Randomization was stratiﬁed by the presence or absence of
medically treated diabetesmellitus, by the intent to treat 1 versus 2
target lesions, andby study site. Exclusion criteria included acute or
recent myocardial infarction (MI), left ventricular ejection fraction
<30%, left main or ostial lesion location, major bifurcation dis-
ease, chronic total occlusion, and target vessel thrombus. Baseline
and post-procedural angiographic data were collected; however,
follow-up angiographic and intravascular ultrasound (IVUS) anal-
yses were performed for clinical indications at the investigator’s
discretion and were not required per protocol. IVUS data and usage
rates were not collected. Follow-up was scheduled for 1, 6, 12, and
18 months and annually from 2 to 5 years. Patients who did not
receive a study stent (either a CoCr-EES or a PtCr-EES) were only
followed through the ﬁrst year post-index procedure.
Antiplatelet therapy
Loading doses of dual antiplatelet therapy (aspirin ≥300mg po
and clopidogrel ≥300mg po) were required in patients not taking
aspirin or a thienopyridine ≥72h prior to the index procedure [6].
Post-percutaneous coronary intervention (PCI) daily aspirin was
required indeﬁnitely, with 162–325mg po daily recommended for
at least the ﬁrst 6 months, and 75–162mg orally daily thereafter.
Clopidogrel 75mg po daily was required for at least 6 months after
stent placement in all patients and for at least 12 months in those
not at high risk of bleeding. Ticlopidine was allowed in patients
intolerant of clopidogrel, and prasugrel was permitted in non-US
sites in accordance with approved country-speciﬁc labeling.
Deﬁnitions
TLF was deﬁned as the composite of cardiac death related to the
target vessel, MI related to the target vessel, or ischemia-driven
target lesion revascularization (TLR) [6]. MI was deﬁned as (i) the
development of newQ-waves in ≥2 leads lasting ≥0.04 swith crea-
tine kinase (CK)MBor troponin levels elevated above normal, or (ii)
in the absence of newQ-waves, elevation of total CK levels >3×nor-
mal (peri-PCI) or >2× normal (spontaneous) with elevated CK-MB,
or troponin >3× normal (peri-PCI) or >2× normal (spontaneous)
plus at least one of the following: (a) electrocardiographic (ECG)
changes indicative of new ischemia [new ST–T changes or left bun-
dle branch block (LBBB)]; (b) imaging evidence of new loss of viable
myocardium; or (c) new regional wall motion abnormality. Sim-
ilar criteria were required for the diagnosis of MI post-coronary
artery bypass graft (CABG), with a CK-MB or troponin threshold of
>5× normal. Ischemia-driven TLR or target vessel revascularization
(TVR) was deﬁned as revascularization with the stenosis ≥50% by
quantitative coronary angiography (QCA) if associated with clin-
ical or functional ischemia (ischemic symptoms, ECG changes, or
positive functional study), or stenosis ≥70% by QCA without doc-
umented ischemia. Stent thrombosis was deﬁned according to the
deﬁnite or probable Academic Research Consortium [ARC] criteria
[16].
Statistical methodology
Baseline, post-procedural, and follow-up data were summa-
rized using descriptive statistics and presented as proportions
(%, count/sample size) or mean± standard deviation. p-Values are
from a two-sided Student t-test for continuous variables and chi-
square or Fisher exact test for discrete variables, as appropriate.
A logistic regression model was used to test for an interaction
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etween stent type and Japanese/non-Japanese subgroup. Survival
nalysis was used to compare differences in TLR between groups
efore and after 1 year; patients must have had at least 366 days of
ollow up to be evaluated in the 1–2 year interval. p-Values were
etermined from the log-rank test comparing the time-to-event
urves from 0 to 1 year and between 1 and 2 years post-procedure.
tatistical signiﬁcance was accepted at p<0.05. All statistical anal-
ses were conducted using SAS software version 8.2 or above (SAS
nstitute Inc., Cary, NC, USA).
esults
atients
A total of 1530 patients were enrolled between January and
eptember2009at132centers, including788patients in theUnited
tates, 562 patients in the European Union, 124 patients in Japan,
nd 56 patients in the Asia Paciﬁc region.
Two-year follow-up was available in 96.0% (719/749) of CoCr-
ES patients and 97.0% (735/758) of PtCr-EES patients, including
00% follow-up in Japanese patients of both study arms (Fig. 1).
aseline patient characteristics
Baseline demographics are shown in Table 1. In Japanese
atients, therewere no statistically signiﬁcant differences between
he randomized stent types. In non-Japanese patients, there were
inor differences in the rates of diabetes controlled by oral hypo-
lycemic agents and diet, and a higher rate of prior transient
schemic attack or cerebrovascular accident in the PtCr-EES group.
Comparing all pooled non-Japanese patients (regardless of stent
ype) to Japanese patients, Japanese patients tended to be older
63.2±10.3 years for non-Japanese vs 67.3±9.0 years for Japanese
ig. 1. Patients included in the analysis. Patients not treated with study stents (CoCr-EES
verolimus-eluting stent; PtCr-EES, platinum chromium everolimus-eluting stent.logy 64 (2014) 105–112 107
patients; p<0.001), were less likely to be currently smoking [20.1%
(271/1345) non-Japanese vs 12.1% (15/124) Japanese; p=0.03], had
a lower incidence of prior MI [21.5% (295/1374) non-Japanese
vs 12.1% (15/124) Japanese; p=0.01], and insulin-treated dia-
betes [7.3% (101/1383) non-Japanese vs 2.4% (3/124) Japanese;
p=0.04], a higher ejection fraction (59.1±9.9% non-Japanese vs
61.9±7.9% Japanese; p=0.002), and a lower rate of familial coro-
nary artery disease history [58.7% (750/1278) non-Japanese vs
23.3% (28/120) Japanese; p<0.001]. However, Japanese patients
tended to have a greater history of multivessel disease compared
to non-Japanese patients [31.9% (440/1379) non-Japanese vs 50.8%
(63/124) Japanese patients; p<0.001].
Amongnon-Japanese, patientswere 92.1%Caucasian, 2.6% black
or African heritage, 2.0%Hispanic or Latino, 1.4% Asian, 0.5% Ameri-
can IndianorAlaskanative, 0.5%nativeHawaiianor Paciﬁc Islander,
0.3% other, 0.1% Maori, and 0.8% undisclosed.
Baseline lesion characteristics
As shown in Table 2, baseline lesion characteristics were well-
matched between the randomized stent types.
Comparing Japanese to non-Japanese patients, Japanese
patients had a greater incidence of tortuous lesions [7.2%
(110/1529) non-Japanese vs 15.1% (21/139) Japanese patients;
p<0.001] and highly complex (American Heart Associa-
tion/American College of Cardiology type B2/C) lesions [63.2%
(967/1529) non-Japanese vs 75.5% (105/139) Japanese patients;
p=0.004]. Otherwise, there were no signiﬁcant differences,
although there was a trend for Japanese patients to have longer
lesions (12.61±5.52mm for non-Japanese patients vs 13.55±5.49
for Japanese patients; p=0.06) and larger reference vessel diameter
(2.64±0.49mm for non-Japanese patients vs 2.72±0.52mm for
Japanese patients; p=0.07).
or PtCr-EES) were not followed beyond the ﬁrst year. CoCr-EES, cobalt chromium
108 S. Saito et al. / Journal of Cardiology 64 (2014) 105–112
Table 1
Baseline patient demographics (patients treated with a study stent).
Japanese cohort Non-Japanese cohort Japanese vs non-Japanese
CoCr-EES (N=61) PtCr-EES (N=63) p value CoCr-EES (N=688) PtCr-EES (N=695) p value p value (CoCr) p value (PtCr)
Age (years) 67.2±10.1 (61) 67.4±8.0 (63) 0.90 62.8±10.2 (688) 63.7±10.4 (695) 0.11 0.001 0.005
Male gender 65.6 (40/61) 74.6 (47/63) 0.27 71.5 (492/688) 71.2 (495/695) 0.91 0.33 0.57
Hyperlipidemiaa 77.0 (47/61) 81.0 (51/63) 0.59 76.2 (523/686) 78.3 (542/692) 0.36 0.89 0.63
Hypertensiona 78.7 (48/61) 74.6 (47/63) 0.59 73.0 (502/688) 70.3 (488/694) 0.27 0.33 0.47
Diabetes (medically
treated)
23.0 (14/61) 19.0 (12/63) 0.59 25.3 (174/688) 21.7 (151/695) 0.12 0.69 0.62
Oral agents 23.0 (14/61) 14.3 (9/63) 0.21 18.5 (127/688) 14.0 (97/695) 0.02 0.39 0.94
Insulin 0.0 (0/61) 4.8 (3/63) 0.24 6.8 (47/688) 7.8 (54/695) 0.50 0.03 0.62
Diabetes treated with
diet control only
4.9 (3/61) 12.7 (8/63) 0.13 1.7 (12/688) 3.9 (27/695) 0.02 0.12 0.006
History of TIA/CVA 9.8 (6/61) 7.9 (5/63) 0.71 4.1 (28/683) 6.8 (47/694) 0.03 0.05 0.61
History of renal disease 4.9 (3/61) 6.3 (4/63) >0.99 2.9 (20/685) 3.0 (21/694) 0.91 0.42 0.15
Smoking, current 13.1 (8/61) 11.1 (7/63) 0.73 18.1 (121/667) 22.1 (150/678) 0.07 0.33 0.04
Smoking, previous 49.2 (30/61) 58.7 (37/63) 0.29 41.7 (278/667) 43.1 (292/678) 0.61 0.26 0.02
Unstable angina 19.7 (12/61) 17.5 (11/63) 0.75 24.9 (171/688) 25.1 (174/694) 0.93 0.37 0.18
Family history of CAD 23.3 (14/60) 23.3 (14/60) 1.00 58.9 (376/638) 58.4 (374/640) 0.86 <0.001 <0.001
Prior MI 6.6 (4/61) 17.5 (11/63) 0.06 21.4 (147/686) 21.5 (148/688) 0.97 0.006 0.45
History of CHF 1.6 (1/61) 3.2 (2/63) >0.99 7.0 (48/684) 7.8 (54/693) 0.58 0.17 0.31
LVEF (%) 60.9±7.5 (61) 62.8±8.3 (63) 0.18 58.9±9.7 (669) 59.3±10.2 (673) 0.45 0.11 0.008
Multivessel disease
history
49.2 (30/61) 52.4 (33/63) 0.72 33.0 (226/685) 30.8 (214/694) 0.39 0.01 <0.001
Left main disease
history
1.6 (1/61) 4.8 (3/63) 0.62 1.3 (9/687) 1.6 (11/692) 0.66 0.58 0.10
Numbers shown are % (count/total) or mean± standard deviation.
C A, cer
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AAD, coronary artery disease; CHF, chronic heart failure; CoCr, cobalt chromium; CV
raction; MI, myocardial infarction; PtCr, platinum chromium; TIA, transient ischem
a Requiring medication.
rocedural characteristics
Differences in procedural characteristics between randomized
tent groups have been previously reported [6] and include higher
mplantation pressure in the PtCr-EES arm and a greater incidence
f unplanned (bailout) and multiple stenting in the CoCr-EES arm
Table 3).
Comparing pooled non-Japanese versus Japanese patients, total
uoroscopy time was signiﬁcantly higher in Japanese patients
espite a signiﬁcantly lower use of contrast (10.4±7.9min
able 2
aseline lesion characteristics (per target lesion).
Japanese cohort Non-Japa
CoCr-EES (N=67
lesions, 61
patients)
PtCr-EES (N=72
lesions, 63
patients)
p value CoCr-EES
lesions, 6
patients)
Target vessel
Left anterior
descending
38.8 (26/67) 34.7 (25/72) 0.62 42.2 (321
Left circumﬂex 25.4 (17/67) 25.0 (18/72) 0.96 26.1 (198
Right coronary
artery
35.8 (24/67) 40.3 (29/72) 0.59 31.7 (241
Target lesion measuresa
Reference vessel
diameter (mm)
2.7±0.5 (67) 2.8±0.5 (72) 0.19 2.6±0.5
Minimal lumen
diameter (mm)
0.7±0.3 (67) 0.8±0.3 (72) 0.51 0.7±0.4
Diameter
stenosis (%)
73.2±10.1 (67) 72.7±10.1 (72) 0.77 71.8±11
Lesion length
(mm)
13.3±5.7 (67) 13.8±5.4 (72) 0.60 12.4±5.5
Bend ≥45◦ 17.9 (12/67) 13.9 (10/72) 0.52 17.0 (129
Tortuosity 11.9 (8/67) 18.1 (13/72) 0.31 6.8 (52/
Total occlusion 0.0 (0/67) 2.8 (2/72) 0.50 0.8 (6/7
ACC/AHA type B2/C
lesions
76.1 (51/67) 75.0 (54/72) 0.88 62.1 (472
umbers shown are % (count/total) or mean± standard deviation.
CC, American College of Cardiology; AHA, American Heart Association; CoCr, cobalt chro
a As reported by angiographic core laboratory.ebrovascular accident; EES, everolimus-eluting stent; LVEF, left ventricular ejection
ack.
and 187.7±86.1 cc for non-Japanese vs 25.3±23.1min and
140.2±66.8 cc for Japanese patients, both p<0.001). Other pro-
cedural characteristics that were signiﬁcantly higher in Japanese
patients included lengthof post-operative stay (1.11±0.80days for
non-Japanese vs 1.98±1.43 days for Japanese patients; p<0.001),
post-dilatation usage [43.7% (724/1530) for non-Japanese vs 77.7%
(108/139) for Japanese patients; p<0.001], and maximum overall
pressure (16.0±3.1 atm for non-Japanese vs 17.1±3.2 atm for
Japanese patients; p<0.001) (Table 3). IVUS data were not
collected.
nese cohort Japanese vs non-Japanese
(N=760
88
PtCr-EES (N=770
lesions, 695
patients)
p value p value (CoCr) p value (PtCr)
/760) 42.5 (327/769) 0.91 0.59 0.20
/760) 26.1 (201/769) 0.97 0.90 0.83
/760) 31.3 (241/769) 0.88 0.49 0.12
(760) 2.7±0.5 (769) 0.22 0.59 0.047
(760) 0.8±0.4 (769) 0.55 0.53 0.94
.6 (760) 71.8±11.5 (769) 0.96 0.34 0.51
(760) 12.8±5.6 (769) 0.10 0.19 0.17
/760) 17.6 (135/769) 0.76 0.85 0.43
760) 7.5 (58/769) 0.60 0.14 0.002
60) 0.4 (3/769) 0.34 >0.99 0.06
/760) 64.4 (495/769) 0.36 0.02 0.07
mium; EES, everolimus-eluting stent; PtCr, platinum chromium.
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Table 3
Procedural characteristics.
Japanese cohort Non-Japanese cohort Japanesevsnon-Japanese
CoCr-EES (N=67
lesions, 61
patients)
PtCr-EES (N=72
lesions, 63
patients)
p value CoCr-EES (N=760
lesions, 688
patients)
PtCr-EES (N=770
lesions, 695
patients)
p value p value
(CoCr)
p value
(PtCr)
Per patient measures
Fluoroscopy time (min) 23.0±20.5 (60) 27.5±25.3 (62) 0.29 10.1±7.5 (634) 10.8±8.2 (649) 0.11 <0.001 <0.001
Contrast used (cc) 143.1±72.9 (61) 137.4±60.7 (63) 0.63 186.6±85.2 (668) 188.7±87.1 (688) 0.66 <0.001 <0.001
Post-procedure hospital
length of stay (days)
2.0±1.3 (61) 2.0±1.5 (63) 0.80 1.1±0.8 (688) 1.1±0.8 (695) 0.89 <0.001 <0.001
1 target lesion treated 90.2 (55/61) 85.7 (54/63) 0.45 89.5 (616/688) 89.2% (620/695) 0.84 0.88 0.40
2 target lesions treated 9.8 (6/61) 14.3 (9/63) 0.45 10.5 (72/688) 10.8% (75/695) 0.84 0.88 0.40
1 target vessel 3.3 (2/61) 4.8 (3/63) >0.99 3.6 (25/688) 3.5% (24/695) 0.86 >0.99 0.48
2 target vessels 6.6 (4/61) 9.5 (6/63) 0.74 6.8 (47/688) 7.3% (51/695) 0.71 >0.99 0.46
Per lesion measures
Pre-dilatation 100.0 (67/67) 100.0 (72/72) – 98.3 (747/760) 98.8% (761/770) 0.37 0.62 >0.99
Post-dilatation 82.1 (55/67) 73.6 (53/72) 0.23 46.6 (354/760) 48.1% (370/770) 0.56 <0.001 <0.001
Maximum dilatation
pressure (atm)a
12.2±2.5 (67) 13.8±2.4 (72) <0.001 13.7±2.8 (760) 14.3±2.5 (767) <0.001 <0.001 0.13
Maximum post-dilatation
pressure (atm)
17.2±3.1 (55) 18.0±3.5 (53) 0.22 16.8±3.8 (354) 17.1±3.8 (370) 0.32 0.43 0.10
Maximum pressure overall
(atm)
16.8±3.0 (67) 17.4±3.4 (72) 0.24 15.8±3.2 (760) 16.3±3.1 (769) 0.002 0.01 0.002
Maximum stent
diameter:RVD ratiob
1.2±0.2 (67) 1.1±0.2 (72) 0.08 1.1±0.2 (751) 1.1±0.2 (765) 0.43 0.004 0.50
Maximum device diameter
per lesion (mm)
3.2±0.4 (67) 3.3±0.5 (72) 0.22 3.1±0.5 (760) 3.2±0.5 (770) 0.03 0.74 0.36
Unplanned stenting
performed (study or
non-study stents)
6.0 (4/67) 1.4 (1/72) 0.20 8.3 (63/760) 5.5% (42/770) 0.03 0.50 0.17
Multiple stents implanted 6.0 (4/67) 1.4 (1/72) 0.20 7.9 (60/760) 4.8% (37/770) 0.01 0.57 0.24
Numbers shown are % (count/total) or mean± standard deviation.
CoCr, cobalt chromium; EES, everolimus-eluting stent; PtCr, platinum chromium; RVD, reference vessel diameter.
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edications
Cardiac, antithrombotic, and antiplatelet medication use is
hown in Table 4. There were no statistically signiﬁcant differences
nmedicationusebetween the randomized stent cohorts.However,
here were several signiﬁcant differences in choice of thienopy-
idine (clopidogrel, ticlopidine, prasugrel) due to availability per
ountry, which led to a signiﬁcant difference between Japanese
ooled patients compared with non-Japanese pooled patients in
he choice of thienopyridine. Ticlopidine was more frequently
referred over clopidogrel in Japanese patients [0.4% (5/1383)
or non-Japanese pooled patients vs 17.7% (22/124) for Japanese
ooled patients at discharge, and 0.2% (3/1320) for non-Japanese
ooled patients vs 12.2% (15/123) for Japanese pooled patients
t 2 years; both p<0.001]. Use of beta-blockers post-procedure
as less frequent in Japanese patients [71.1% for non-Japanese
ooled patients (98/1383) vs 36.3% (45/124) for Japanese pooled
atients at hospital discharge; p<0.001]. Dual antiplatelet usage
as signiﬁcantly higher in Japanese compared to non-Japanese
atients at both 1- and 2-years post-implantation [1 year: 80.5%
1101/1368) for non-Japanese pooled patients vs 98.4% (121/123)
or Japanesepooledpatients, and2years: 46.4% (620/1337) fornon-
apanese pooled patients vs 86.2% (106/123) for Japanese pooled
atients; both p<0.001]; this difference was predominantly driven
y thienopyridine use as aspirin use was not signiﬁcantly differ-
nt between non-Japanese and Japanese patients at 2 years [93.6%
1251/1337) vs 95.9% (118/123), respectively; p=0.30].wo-year clinical outcomes
In the overall PLATINUMstudy, PtCr-EESwas non-inferior to the
oCr-EES for the1-year primary endpoint of TLF,withno signiﬁcantom no study stent was implanted.
differences in death, MI, TVR, or stent thrombosis [6]. Outcomes
were consistent through 2 years, with TLF rates of 4.4% and 5.8% for
the PtCr-EES and CoCr-EES stents, respectively [8].
Similarly, no signiﬁcant differences were observed between
stent types in either the Japanese or non-Japanese cohorts (Table 5)
and there were no signiﬁcant interaction effects for all-cause death
(p=0.50), cardiac death (p=0.98), MI (p=0.97), TVR (p=0.43),
TLR (p=0.54), TLF (p=0.82), or deﬁnite/probable stent thrombo-
sis (p=0.98). TLF was not signiﬁcantly different between stents for
Japanese patients, with 2-year rates of 4.9% (CoCr-EES) and 3.2%
(PtCr-EES; Fig. 2).
There were no signiﬁcant differences in late outcome measures
between Japanese and non-Japanese cohorts in either stent group,
nor in the pooled analysis of Japanese versus non-Japanese patients
regardless of stent type, with the single exception of a signiﬁcantly
lower rate of MI not related to the target vessel in non-Japanese
patients treatedwith PtCr-EES, likely due to chance. This difference
in the PtCr-EES non-Japanese arm also contributed to an overall
signiﬁcant difference in MI not related to the target vessel between
Japanese and non-Japanese patients regardless of stent type [0.2%
for non-Japanese patients (2/1325) vs 1.6% (2/124) for Japanese
patients; p=0.04]. Despite less use of clopidogrel and more use
of ticloplidine in Japanese versus non-Japanese patients through
2 years, there was no signiﬁcant difference in the stent thrombosis
rates, although the small sample size of the Japanese cohort limited
the ability to detect signiﬁcant differences.
DiscussionStudies have suggested that stent deployment techniques may
be different in Japan compared to other countries, including
greater usage of post-dilatation, higher implantation pressure, and
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Table 4
Cardiac, antithrombotic, and antiplatelet medications.
Japanese cohort Non-Japanese cohort Japanese vs non-Japanese
CoCr-EES (N=61) PtCr-EES (N=63) p value CoCr-EES (N=688) PtCr-EES (N=695) p value p value (CoCr) p value (PtCr)
Prior regimen or loading dose
Aspirin 100.0 (61/61) 100.0 (63/63) – 99.4 (684/688) 99.3 (690/695) >0.99 >0.99 >0.99
Clopidogrel 82.0 (50/61) 81.0 (51/63) 0.88 98.1 (675/688) 98.1 (682/695) 0.98 <0.001 <0.001
Ticlopidine 18.0 (11/61) 20.6 (13/63) 0.71 0.6 (4/688) 0.6 (4/695) >0.99 <0.001 <0.001
Prasugrel 0.0 (0/61) 0.0 (0/63) – 0.3 (2/688) 0.4 (3/695) >0.99 >0.99 >0.99
During procedure
GP IIb/IIIa inhibitor 0.0 (0/61) 0.0 (0/63) – 8.4 (58/688) 7.6 (53/695) 0.58 0.01 0.02
Heparin/other
anti-thrombin
100.0 (61/61) 100.0 (63/63) – 99.3 (683/688) 99.1 (689/695) 0.78 >0.99 >0.99
Intracoronary NTG or
isosorbide dinitrate
100.0 (61/61) 100.0 (63/63) – 86.0 (592/688) 89.2 (620/695) 0.07 0.002 0.006
Discharge
Warfarin 0.0 (0/61) 1.6 (1/63) >0.99 0.1 (1/688) 0.3 (2/695) >0.99 >0.99 0.23
Beta blockers 29.5 (18/61) 42.9 (27/63) 0.12 72.7 (500/688) 69.5 (483/695) 0.19 <0.001 <0.001
ACE inhibitors/all
antagonists
52.5 (32/61) 50.8 (32/63) 0.85 60.3 (415/688) 59.9 (416/695) 0.86 0.23 0.16
Aspirin 100.0 (61/61) 100.0 (63/63) – 99.6 (685/688) 98.8 (687/695) 0.13 >0.99 >0.99
Clopidogrel 83.6 (51/61) 81.0 (51/63) 0.70 99.1 (682/688) 98.1 (682/695) 0.11 <0.001 <0.001
Ticlopidine 16.4 (10/61) 19.0 (12/63) 0.70 0.1 (1/688) 0.6 (4/695) 0.37 <0.001 <0.001
Prasugrel 0.0 (0/61) 0.0 (0/63) – 0.1 (1/688) 0.1 (1/695) >0.99 >0.99 >0.99
DAPT 100.0 (61/61) 100.0 (63/63) – 98.8 (680/688) 97.8 (680/695) 0.15 >0.99 0.63
12-Month follow-up
Aspirin 100.0 (61/61) 96.8 (60/62) 0.50 93.1 (634/681) 94.5 (649/687) 0.29 0.03 0.77
Clopidogrel 88.5 (54/61) 82.3 (51/62) 0.33 80.0 (545/681) 82.1 (564/687) 0.33 0.11 0.97
Ticlopidine 11.5 (7/61) 14.5 (9/62) 0.62 0.3 (2/675) 0.7 (5/680) 0.45 <0.001 <0.001
Prasugrel 0.0 (0/61) 0.0 (0/62) – 1.0 (7/675) 0.9 (6/680) 0.77 >0.99 >0.99
DAPT 100.0 (61/61) 96.8 (60/62) 0.50 78.7 (536/681) 82.2 (565/687) 0.10 <0.001 0.003
24-Month follow-up
Aspirin 95.1 (58/61) 96.8 (60/62) 0.68 92.5 (614/664) 94.7 (637/673) 0.10 0.61 0.76
Clopidogrel 75.4 (46/61) 74.2 (46/62) 0.88 46.5 (309/664) 48.6 (327/673) 0.45 <0.001 <0.001
Ticlopidine 11.5 (7/61) 12.9 (8/62) 0.81 0.2 (1/656) 0.3 (2/664) >0.99 <0.001 <0.001
Prasugrel 0.0 (0/61) 0.0 (0/62) – 0.9 (6/656) 1.8 (12/664) 0.16 >0.99 0.61
DAPT 85.2 (52/61) 87.1 (54/62) 0.77 44.6 (296/664) 48.1 (324/673) 0.19 <0.001 <0.001
Numbers shown are % (count/total).
ACE, angiotensin-converting enzyme; DAPT, dual antiplatelet therapy (aspirin, plus clopidogrel, ticlopidine, or prasugrel); GP, glycoprotein; NTG, nitroglycerin; CoCr-EES,
cobalt chromium everolimus-eluting stent; PtCr-EES, platinum chromium everolimus-eluting stent.
Table 5
Two-year clinical outcomes.
Japanese cohort Non-Japanese cohort Japanese vs non-Japanese
CoCr-EES (N=61) PtCr-EES (N=63) p value CoCr-EES (N=688) PtCr-EES (N=695) p value p value (CoCr) p value (PtCr)
All-cause death, MI, TVR 6.6 (4/61) 7.9 (5/63) >0.99 9.2 (60/655) 7.9 (53/670) 0.42 0.50 >0.99
All-cause death or MI 1.6 (1/61) 6.3 (4/63) 0.37 4.9 (32/655) 3.9 (26/670) 0.37 0.35 0.32
All death 1.6 (1/61) 3.2 (2/63) >0.99 2.9 (19/655) 2.4 (16/670) 0.56 >0.99 0.66
Cardiac death 0.0 (0/61) 1.6 (1/63) >0.99 1.7 (11/655) 0.9 (6/670) 0.20 0.61 0.47
TV-related 0.0 (0/61) 1.6 (1/63) >0.99 1.1 (7/655) 0.9 (6/670) 0.75 >0.99 0.47
Not TV-related 0.0 (0/61) 0.0 (0/63) – 0.6 (4/655) 0.0 (0/670) 0.06 >0.99 –
Non-cardiac death 1.6 (1/61) 1.6 (1/63) >0.99 1.2 (8/655) 1.5 (10/670) 0.67 0.55 >0.99
MI 0.0 (0/61) 3.2 (2/63) 0.50 2.3 (15/655) 1.5 (10/670) 0.29 0.63 0.28
TV-related 0.0 (0/61) 0.0 (0/63) – 2.1 (14/655) 1.3 (9/670) 0.27 0.62 >0.99
Not TV-related 0.0 (0/61) 3.2 (2/63) 0.50 0.2 (1/655) 0.1 (1/670) >0.99 >0.99 0.02
Q-wave MI 0.0 (0/61) 1.6 (1/63) >0.99 0.9 (6/655) 0.1 (1/670) 0.07 >0.99 0.16
Non-Q-wave MI 0.0 (0/61) 1.6 (1/63) >0.99 1.7 (11/655) 1.3 (9/670) 0.62 0.61 0.60
TVR, overall 4.9 (3/61) 1.6 (1/63) 0.36 5.5 (36/655) 4.5 (30/670) 0.39 >0.99 0.51
TLR, overall 4.9 (3/61) 1.6 (1/63) 0.36 3.8 (25/655) 2.5 (17/670) 0.18 0.72 >0.99
TLR, PCI 3.3 (2/61) 1.6 (1/63) 0.62 3.5 (23/655) 1.9 (13/670) 0.08 >0.99 >0.99
TLR, CABG 1.6 (1/61) 0.0 (0/63) 0.49 0.3 (2/655) 0.6 (4/670) 0.69 0.23 >0.99
Non-TLR TVR, overall 0.0 (0/61) 0.0 (0/63) – 2.0 (13/655) 2.2 (15/670) 0.75 0.62 0.63
Cardiac death or MI 0.0 (0/61) 4.8 (3/63) 0.24 3.7 (24/655) 2.4 (16/670) 0.17 0.25 0.22
Target lesion failure 5.0 (3/60) 3.2 (2/62) 0.68 5.9 (38/643) 4.7 (31/660) 0.33 >0.99 >0.99
Target vessel failure 5.0 (3/60) 3.2 (2/62) 0.68 7.3 (47/643) 6.4 (42/660) 0.50 0.79 0.57
Stent thrombosis (ARC
deﬁnite or probable)
0.0 (0/60) 1.6 (1/61) >0.99 0.6 (4/637) 0.5 (3/653) 0.72 >0.99 0.30
Deﬁnite 0.0 (0/60) 1.6 (1/61) >0.99 0.6 (4/637) 0.5 (3/653) 0.72 >0.99 0.30
Probable 0.0 (0/60) 0.0 (0/61) – 0.0 (0/637) 0.0 (0/653) – – –
Numbers shown are % (count/total).
CoCr-EES, cobalt chromium everolimus-eluting stent; PtCr-EES, platinum chromium everolimus-eluting stent; ARC, Academic Research Consortium; CABG, coronary artery
bypass graft; MI, myocardial infarction; PCI, percutaneous coronary intervention; TV, target vessel; TLR, target lesion revascularization; TVR, target vessel revascularization.
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Fig. 2. Target lesion revascularization (TLR) through 2-year follow-up. (A) TLR
through 2 years; (B) survival analysis evaluating 0–1 year and 1–2 year TLR. CoCr-
EES: N=61 at time 0, n=60 at 1 year; PtCr-EES: N=63 at time 0, n=61 at 1 year.
CoCr-EES, cobalt chromiumeverolimus-eluting stent; PtCr-EES, platinumchromium
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ore frequent use of intravascular ultrasound guidance [9,12,13].
n addition, potential differences in patient demographics and
ifestyle (e.g. food choices, body mass index, diabetes) warrant
nvestigation of novel stents speciﬁcally in Japanese populations.
The current paper describes outcomes of the Japanese and non-
apanese cohorts of the PLATINUM randomized controlled trial,
hich compared the PROMUS Element and XIENCE V (PROMUS)
tents. The key outcomes of this subanalysis include: (1) follow-
p rates were high in Japanese patients (100%); (2) at baseline,
apanese patients tended to be older and have a greater incidence
f arrhythmia and multivessel disease than non-Japanese patients,
lthough prior MI incidence was lower and ejection fraction was
igher. In addition, lesion complexity tended to be higher in
apanese patients; (3) procedural differences included signiﬁcantly
onger ﬂuoroscopy time and signiﬁcantly lower use of contrast in
apan, as well as greater post-dilation usage and higher maximum
nﬂation pressures; (4) despite differences in baseline patient and
esion characteristics and procedural practice patterns, as well as
igniﬁcantly higher dual antiplatelet therapy usage at 2 years, out-
omes were similar between Japanese and non-Japanese patients,
ith no signiﬁcant differences in mortality, MI, stent thrombo-
is, or revascularization rates; and (5) consistent with the overalllogy 64 (2014) 105–112 111
PLATINUMstudy [6], therewere no signiﬁcant differences between
CoCr-EES and PtCr-EES in Japanese patients.
Comparing CoCr-EES versus PtCr-EES in Japanese and non-
Japanese patients, the results of this analysis are consistent with
prior studieswhichdemonstratedno signiﬁcantdifferences in rates
of death,MI, revascularization, and stent thrombosis between these
two stent types [17,18].
Differences in baseline patient and lesion characteristics
between Japanese and non-Japanese patients were similar to a
report comparing the SPIRIT III Japan and SPIRIT III USA stud-
ies, showing that the Japan cohort was signiﬁcantly older, had
lower body mass index, smaller waist circumference, less hyper-
cholesterolemia, less unstable angina, and lower family history of
coronary artery disease than the USA arm [13]. In addition, the
current analysis is consistent with previous reports demonstrat-
ing that post-dilatation use and implantation pressure tend to be
higher in Japanese versus non-Japanese centers [9,12,13]. In the
SPIRIT III analysis, it was suggested that higher maximum balloon
pressure and/ormorepostdilatationwithout excess tissueprolapse
or edge dissection resulted in lower incomplete stent apposition
rates in Japanese versus non-Japanese patients (15.9% vs 33.3%,
p=0.006) [13]. While incomplete apposition rates are reportedly
lower with the PROMUS Element compared to the XIENCE V stent
used in SPIRIT III [19], IVUS outcomes are not available in the cur-
rent PLATINUM analysis.
Despite the observed differences in baseline patient, lesion, and
procedural characteristics, there were no signiﬁcant differences
in 2-year clinical outcomes between Japanese and non-Japanese
patients. Safety event rates in Japanese patients were slightly
higher than those observed in the PLATINUM Japan Small Vessel
study of the PROMUSElement stent,which reportednodeaths,MIs,
or stent thromboses through 12 months, although sample sizes of
both studies are underpowered. TLR rates across the 2 studieswere
similar [20].
The current analysis demonstrated signiﬁcantly higher dual
antiplatelet therapy use in Japanese versus other countries
(approximately 86% in Japan vs 46% in other countries at 2 years
post-procedure), again consistent with prior reports. It has been
suggested that this increased use of antiplatelet therapy results in
lower stent thrombosis rates in Japan compared to Western coun-
tries [12,21]. In the current analysis, 2-year stent thrombosis rates
were similar between Japanese and non-Japanese patients, despite
the discrepancy in dual antiplatelet therapy usage. However, the
sample size of the Japanese cohort limited the ability to detect
signiﬁcant differences.
Limitations
Since patients and lesions chosen for inclusion in these studies
were carefully selected, the results may not be representative of
more complex lesions. Patients with acute MI, chronic total occlu-
sion, bifurcation lesions, left main lesions, saphenous vein graft
lesions, ostial lesions, or lesions with thrombus or excessive tor-
tuosity or calciﬁcation were excluded. In addition, differences in
baseline characteristics, medical management, concomitant ther-
apy between Japanese and non-Japanese cohorts may have had
an impact on the 2-year outcomes. Finally, this substudy was not
powered to detect differences between Japanese and non-Japanese
subgroups.The results of this study suggest that PtCr-EES provide compa-
rable safety and efﬁcacy outcomes in Japanese and non-Japanese
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atients, with similar outcomes to the CoCr-EES in both geograph-
cal populations.
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